Compositions comprising bacterial strains

Abstract

Provided are compositions comprising a bacterial strain of the genus Blautia , for use in a method of increasing the microbiota diversity and/or stability of the microbiota of a subject.

1 .- 40 . (canceled) 
     
     
         41 . A method of inducing a temporal variation in the microbiota of a subject having a stroke in need thereof, comprising administering to the subject a composition that comprises a therapeutically effective amount of a bacteria strain of the genus  Blautia  with at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO:5, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62, wherein the administering is effective to induce the temporal variation in the microbiota of the subject having the stroke. 
     
     
         42 . The method of  claim 41 , wherein the subject has the stroke and the administering induces a temporal increase of a bacteria of the species  Mucispirillum schaedleri , from the family Lachnospiraceae, from the family Ruminococcaceae, from the genus  Clostridium  XIVa, or of the species  Oscillibacter valericigenes , or a temporal decrease of the species  Barnesiella intestinihominis , of the species  Ruminococcus flavefaciens , of the species  Alistipes finegoldii , of the species  Staphylococcus lentus , from the genus  Staphylococcus , from the genus  Prevotella , from the genus  Barnesiella , from the family Lachnospiraceae, or of the species  Lactobacillus johnsonii .    
     
     
         43 . The method of  claim 41 , wherein the bacteria strain is dried. 
     
     
         44 . The method of  claim 41 , wherein the pharmaceutical composition comprises de minimis amounts of other bacterial strains. 
     
     
         45 . The method of  claim 41 , wherein the therapeutically effective amount of the bacteria strain comprises from about 1×10 3  to about 1×10 11  colony forming units (CFU)/g of the bacteria strain with respect to the total weight of the pharmaceutical composition. 
     
     
         46 . The method of  claim 41 , wherein the therapeutically effective amount of the bacteria strain comprises at least 1×10 6  CFU/g of the bacteria strain with respect to the total weight of the pharmaceutical composition. 
     
     
         47 . The method of  claim 41 , wherein the bacteria strain comprises a polynucleotide sequence of a 16S rRNA gene that has at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO:5, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12, a gap extension penalty of 2, and a Blocks Substitution Matrix (BLOSUM) of 62. 
     
     
         48 . The method of  claim 41 , wherein the bacteria strain comprises the polynucleotide sequence of SEQ ID NO:5. 
     
     
         49 . The method of  claim 41 , wherein the bacteria strain is of the species  Blautia hydrogenotrophica.    
     
     
         50 . The method of  claim 41 , wherein the bacteria strain is the strain deposited under accession number DSM 10507 or the strain deposited under accession number DSM 14294. 
     
     
         51 . The method of  claim 41 , wherein said administering comprises oral, rectal, nasal, buccal, sublingual, or subcutaneous administration. 
     
     
         52 . The method of  claim 41 , wherein the pharmaceutical composition is formulated for delivery to an intestine of the subject. 
     
     
         53 . The method of  claim 41 , wherein the pharmaceutical composition is encapsulated. 
     
     
         54 . The method of  claim 41 , wherein the pharmaceutical composition comprises an enteric coating. 
     
     
         55 . The method of  claim 41 , further comprising administering an additional therapeutic agent to the subject. 
     
     
         56 . The method of  claim 41 , wherein the pharmaceutical composition further comprises a pharmaceutically acceptable excipient, diluent, or carrier. 
     
     
         57 . The method of  claim 41 , wherein the subject is a human.